Regenxbio Signs an Exclusive Worldwide Option and License Agreement with Clearside Biomedical to Evaluate its Delivery Platform for RGX-314

 Regenxbio Signs an Exclusive Worldwide Option and License Agreement with Clearside Biomedical to Evaluate its Delivery Platform for RGX-314

REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology

Shots:

  • Clearside to receive ~$34M as development milestones, ~$102M commercial milestones, option exercise fee and royalties on sales of product utilizing SCS microinjector. Regenxbio to get an option to receive an exclusive WW commercial license with rights to sublicense Clearside’s SCS microinjector to deliver AAV gene therapies for wet AMD, DR and other chronic anti-VEGF conditions
  • Regenxbio expands RGX-314 gene therapy program utilizing Clearside’s SCS microinjector for non-surgical delivery targeting the suprachoroidal in addition to its ongoing subretinal delivery program with a P-IIb study in wet AMD and P-II study in DR with its expected initiation in H2’19
  • Regenxbio’s RGX-314 comprises of NAV AAV8 vector encoding an Ab fragment inhibiting VEGF thus modify the pathway for the formation of new leaky blood vessels leading the accumulation of retinal fluid and vision loss

Click here to­ read full press release/ article | Ref: Regenxbio | Image: Regenxbio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post